Chemed Co. (NYSE:CHE) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its holdings in shares of Chemed Co. (NYSE:CHEGet Rating) by 3.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 55,848 shares of the company’s stock after selling 2,174 shares during the period. Principal Financial Group Inc. owned approximately 0.36% of Chemed worth $29,546,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Altshuler Shaham Ltd lifted its position in shares of Chemed by 23.5% in the 3rd quarter. Altshuler Shaham Ltd now owns 105 shares of the company’s stock valued at $49,000 after acquiring an additional 20 shares in the last quarter. Fiduciary Planning LLC lifted its position in shares of Chemed by 1.7% in the 4th quarter. Fiduciary Planning LLC now owns 1,732 shares of the company’s stock valued at $916,000 after acquiring an additional 29 shares in the last quarter. Shell Asset Management Co. lifted its position in shares of Chemed by 1.0% in the 4th quarter. Shell Asset Management Co. now owns 3,163 shares of the company’s stock valued at $1,673,000 after acquiring an additional 31 shares in the last quarter. Spire Wealth Management lifted its position in shares of Chemed by 42.5% in the 4th quarter. Spire Wealth Management now owns 114 shares of the company’s stock valued at $60,000 after acquiring an additional 34 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its position in shares of Chemed by 6.9% in the 4th quarter. CIBC Asset Management Inc now owns 617 shares of the company’s stock valued at $326,000 after acquiring an additional 40 shares in the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

In other news, CEO Kevin J. Mcnamara sold 3,000 shares of the stock in a transaction on Tuesday, March 8th. The shares were sold at an average price of $469.91, for a total transaction of $1,409,730.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Spencer S. Lee sold 1,054 shares of the stock in a transaction on Monday, March 7th. The stock was sold at an average price of $487.39, for a total transaction of $513,709.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,891 shares of company stock worth $7,316,570. 4.03% of the stock is currently owned by company insiders.

CHE stock opened at $498.94 on Friday. Chemed Co. has a 12-month low of $403.00 and a 12-month high of $539.87. The company has a quick ratio of 0.62, a current ratio of 0.66 and a debt-to-equity ratio of 0.18. The company has a market cap of $7.47 billion, a price-to-earnings ratio of 29.19, a PEG ratio of 3.01 and a beta of 0.53. The company has a 50 day moving average of $494.20 and a two-hundred day moving average of $490.26.

Chemed (NYSE:CHEGet Rating) last released its earnings results on Tuesday, April 26th. The company reported $4.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.47 by $0.32. Chemed had a net margin of 12.48% and a return on equity of 41.96%. During the same period in the prior year, the business posted $4.44 earnings per share. On average, research analysts anticipate that Chemed Co. will post 19.09 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 18th. Stockholders of record on Monday, February 28th were paid a dividend of $0.36 per share. The ex-dividend date of this dividend was Friday, February 25th. This represents a $1.44 annualized dividend and a dividend yield of 0.29%. Chemed’s dividend payout ratio (DPR) is 8.43%.

Several brokerages recently commented on CHE. StockNews.com began coverage on shares of Chemed in a research report on Thursday, March 31st. They issued a “buy” rating for the company. Royal Bank of Canada reduced their price target on shares of Chemed from $609.00 to $579.00 and set an “outperform” rating for the company in a research report on Friday, March 4th. Finally, Zacks Investment Research upgraded shares of Chemed from a “hold” rating to a “buy” rating and set a $496.00 target price for the company in a research report on Friday, January 21st.

Chemed Company Profile (Get Rating)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Stories

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEGet Rating).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.